Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy

Xiaohui Wang1, Ying Yu2, Lingna Zang3

  • 1Department of Orthopedics, Linyi Central Hospital, Linyi, Shandong 276000, China.

Abstract

Insights

High-Grade Osteosarcoma (HGOS) patients with higher soluble CLU (sCLU) expression showed increased metastasis and poorer chemotherapy response. Targeting sCLU may offer a new therapeutic strategy for osteosarcoma (OS).

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • High-Grade Osteosarcoma (HGOS) is an aggressive bone cancer with limited treatment options.
  • Soluble CLU (sCLU), a secreted form of Clusterin, has been implicated in various cancers, but its role in HGOS is not fully understood.

Purpose of the Study:

  • To investigate the association between sCLU expression and clinicopathological features in HGOS patients.
  • To evaluate sCLU as a potential therapeutic target for osteosarcoma (OS).

Main Methods:

  • Immunohistochemistry was used to assess sCLU expression in 98 HGOS patient samples.
  • Correlation analysis was performed between sCLU levels, clinical data, and patient survival.
  • In vitro studies using U2OS cells evaluated the effects of sCLU gene silencing on apoptosis, viability, invasion, and chemosensitivity to doxorubicin.

Main Results:

  • sCLU expression was detected in 60% of HGOS patients.
  • Positive correlation between sCLU expression and metastatic disease (P = 0.036).
  • Negative correlation between sCLU expression and response to chemotherapy (P = 0.002).
  • In vitro, sCLU targeting reduced U2OS cell growth, increased apoptosis, inhibited invasion, and enhanced doxorubicin sensitivity.

Conclusions:

  • Overexpressed sCLU is significantly correlated with metastasis and chemoresistance in HGOS.
  • sCLU represents a promising therapeutic and chemopreventive target for osteosarcoma treatment.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
678
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
820
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
14.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
607
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
600
Receptor-mediated Endocytosis01:39

Receptor-mediated Endocytosis

Overview
110.6K